Mark Saad, CFO at Plus Therapeutics, holds 10.10K shares in Axsome Therapeutics (Ticker: AXSM), holds 13.75K shares in Catheter Precision (Ticker: VTAK), holds 276.86K shares in Plus Therapeutics (Ticker: PSTV). Most recently, Mark Saad Bought ― shares of Axsome Therapeutics on Nov 19, 2021 for an estimated value of 113.91K.